Online inquiry

IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ430MR)

This product GTTS-WQ430MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets AMHR2 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001164690.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 269
UniProt ID Q16671
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ430MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9611MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ10676MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ8906MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IGE25
GTTS-WQ4523MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ8371MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ2211MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ9135MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN-289
GTTS-WQ8436MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HspE7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW